Yeast cells arrest in the G1 phase of the cell cycle upon exposure to mating pheromones. As cells commit to a new cycle, G1 CDK activity (Cln/CDK) inhibits signaling through the mating MAPK cascade. Here we show that the target of this inhibition is Ste5, the MAPK cascade scaffold protein. Cln/CDK disrupts Ste5 membrane localization by phosphorylating a cluster of sites that flank a small, basic, membranebinding motif in Ste5. Effective inhibition of Ste5 signaling requires multiple phosphorylation sites and a substantial accumulation of negative charge, which suggests that Ste5 acts as a sensor for high G1 CDK activity. Thus, Ste5 is an integration point for both external and internal signals. When Ste5 cannot be phosphorylated, pheromone triggers an aberrant arrest of cells outside G1 either in the presence or absence of the CDK-inhibitor protein Far1. These findings define a mechanism and physiological benefit of restricting antiproliferative signaling to G1.
INTRODUCTION
Cellular decisions are commonly regulated by external signals via mitogen-activated protein (MAP) kinase cascades (Qi and Elion, 2005) . Though widely appreciated to stimulate cell proliferation, MAP kinase (MAPK) pathways can also regulate cell differentiation. Relatively little is known about how differentiation and antiproliferative signals may be integrated with or counteracted by the cell-division status of individual cells. In yeast, mating pheromones activate a MAPK cascade to trigger fusion between two haploid gamete cells (Dohlman and Thorner, 2001 ). This mating reaction exhibits fundamental hallmarks of differentiation: cells exit the cell cycle, induce a unique program of gene expression, and undergo morphogenetic changes that allow them to adopt a new fate. Mating pheromones cause cells to arrest specifically in the G1 stage of the cell cycle prior to the G1 / S transition step known as ''Start.'' However, cells that have already passed Start become refractory to pheromone arrest; this property was used to define Start as a unique point of commitment to a new round of division (Hartwell et al., 1974) .
One contributor to the G1 specificity of pheromone arrest is the mutual antagonism between cyclin-dependent kinases (CDKs) and Far1, a CDK inhibitor (Chang and Herskowitz, 1990) . Pheromone signaling in G1 cells allows the MAPK Fus3 to phosphorylate and activate Far1 (Chang and Herskowitz, 1992; Breitkreutz et al., 2001 ), which in turn inhibits CDK activity associated with G1 cyclin (Cln) proteins by an unresolved mechanism (Peter and Herskowitz, 1994; Gartner et al., 1998; Jeoung et al., 1998) . Conversely, as cells pass Start, Cln/CDKs phosphorylate Far1 and target it for degradation (McKinney et al., 1993; Henchoz et al., 1997) . However, other mechanisms may play an equally critical role in restricting pheromone arrest to G1, but they are poorly understood. In particular, signal transduction through the MAPK cascade is actively inhibited by G1 CDKs in a way such that pheromoneinduced transcription of mating genes (e.g., FUS1) is minimized during periods of maximum G1 cyclin expression (Oehlen and Cross, 1994; Wassmann and Ammerer, 1997) . As a result, cells are unresponsive to pheromone during a period that runs from Start through S phase.
While G1 CDK inhibition of pheromone signaling has been recognized for many years, the target and mechanism have remained elusive. Previous studies suggested that the inhibited step of the signaling pathway lay somewhere between the heterotrimeric G protein bg dimer (Gbg) and the first kinase of the MAPK cascade, the MAPKKK Ste11 (Wassmann and Ammerer, 1997; . Indeed, Cln2/CDK can phosphorylate the PAK-family kinase Ste20 Wu et al., 1998) , but removing CDK sites in Ste20 had no effect on the ability of Cln/CDK to inhibit pheromone signaling (Oda et al., 1999) . Thus, this failed to confirm Ste20 as a relevant target. In the interim, our understanding of this signaling pathway has advanced considerably.
An important step in activation of the mating pathway (see Figure 1A) is the plasma membrane recruitment of the MAPK cascade scaffold protein Ste5 by the pheromone-activated Gbg dimer (Pryciak and Huntress, 1998; Mahanty et al., 1999; van Drogen et al., 2001; Winters et al., 2005) . Indeed, artificial targeting of Ste5 to the plasma membrane causes constitutive signaling (Pryciak and Huntress, 1998) . Membrane recruitment of Ste5 serves two roles: (1) it promotes activation of Ste11 by its membrane-localized activator, Ste20 (Pryciak and Huntress, 1998; van Drogen et al., 2000) , and (2) it amplifies signal transmission from active Ste11 through the remainder of the kinase cascade (Lamson et al., 2006) . Recently, we found that although Gbg is the usual trigger for Ste5 recruitment, it is not sufficient. Instead, Ste5 also binds directly to membranes, and cooperativity between these two weak interactions (Ste5-Gbg and Ste5-membrane) controls membrane recruitment (Winters et al., 2005) . The Ste5-membrane interaction requires an N-terminal ''PM'' (plasma membrane-binding) domain, which is a short basic-rich amphipathic a helix that binds acidic phospholipid membranes and which can also target Ste5 to the nucleus when it is not engaged at the plasma membrane. Gain-of-function mutations in the PM domain cause increased membrane affinity, which allows Ste5 to localize to the plasma membrane and activate signaling even without Gbg (Winters et al., 2005) .
In this study, we report that G1 CDK activity inhibits pheromone signaling by inhibiting Ste5 membrane recruitment. The Ste5 PM domain is flanked by multiple CDK sites that are phosphorylated by G1 CDKs in vivo and in vitro, and the addition of multiple negatively charged phosphates impedes binding to acidic phospholipid membranes. Furthermore, we show that when CDK regulation of Ste5 is disrupted, pheromone signaling blocks cell-cycle progression even after cells pass Start and even in the absence of Far1; this provides a physiological rationale for antagonizing pheromone signaling as cells begin a new division cycle. From left to right, they are: a factor (af) treatment or Gb overexpression (Whiteway et al., 1990) ; hyperactive membrane localization of Ste5 via an enhanced PM domain (Winters et al., 2005) ; membrane targeting of Ste5 via a foreign transmembrane domain (Pryciak and Huntress, 1998) ; and membrane targeting of Ste11 via a prenylation/palmitoylation motif (Winters et al., 2005) . (C) Cln2/CDK inhibition correlates with dependence on the Ste5 PM domain. Pathway-activating components were expressed from the GAL1 promoter and were compared for their ability to induce FUS1-lacZ transcription in ste4D strains ± P GAL1 -CLN2 (n = 4).
(D) Ste20-independent signaling is sensitive to Cln2 inhibition. Wildtype Ste11 (WT) or a Ste20-independent mutant (Ste11-Asp3) was expressed in ste11D or ste11D ste20D strains ± P GAL1 -CLN2. FUS1-lacZ induction was measured after a factor treatment (n = 6). (E) PM domain mutations that disrupt nuclear targeting (NLSm) do not affect Cln2 inhibition. FUS1-lacZ was induced by a factor treatment in ste5D ± P GAL1 -CLN2 strains expressing Ste5-WT or Ste5-NLSm (n = 9). (F) Increased Ste5 membrane affinity causes increased resistance to Cln2. Left: Ste5 variants contained PM domain mutations that increase membrane affinity. Right: the native PM domain was replaced with one or two copies of the PLCd PH domain. All forms were expressed from the native STE5 promoter in ste5D strains ± P GAL1 -CLN2, and response to a factor was measured (n = 4-9). Data in all bar graphs show the mean ± SD.
RESULTS

G1 CDKs Inhibit the Function of the Ste5 PM Domain
To identify the target of Cln/CDK inhibition we used several new tools to dissect early steps in the mating pathway. First, activated forms of various pathway components ( Figure 1B ) were expressed from a strong, galactose-inducible promoter (P GAL1 ) to bypass upstream signaling steps. We then compared signaling with and without overexpression of Cln2, which is the G1 cyclin that is most potent at inhibiting pheromone response (Oehlen and Cross, 1994) . While each activation method caused strong signaling, only those that required the Ste5 PM domain could be inhibited by Cln2 ( Figure 1C ). Especially revealing is the comparison between Ste5-Q59L and Ste5-CTM. Both activate signaling by targeting Ste5 to the plasma membrane, and both bypass Gbg but still require Ste20 (Pryciak and Huntress, 1998; Winters et al., 2005 ), yet they behaved oppositely with regard to Cln2 sensitivity: Ste5-Q59L (which is targeted to the membrane by an enhanced PM domain; Winters et al., 2005) was sensitive to Cln2 inhibition, whereas Ste5-CTM (which is targeted to the membrane by a foreign transmembrane domain; Pryciak and Huntress, 1998) was resistant. Furthermore, when comparing two Ste11 derivatives, we found that Ste11-Cpr (which requires the Ste5 PM domain; Winters et al., 2005) remained sensitive to Cln2 inhibition, whereas Ste11DN (which bypasses Ste5 altogether; Pryciak and Huntress, 1998) was resistant. These results argue that G1 CDK inhibition does not act on Gbg, Ste20, Ste11, or even the ability of Ste5 to facilitate signaling through the MAPK cascade. Instead, signaling is inhibited only when membrane localization by the Ste5 PM domain is required.
In addition to promoting the initial Ste20 / Ste11 step, membrane localization of Ste5 serves a second, Ste20-independent role in boosting signal transmission from active Ste11 through the MAPK cascade (Lamson et al., 2006) . Because of this ''amplification'' effect, pheromone can stimulate signaling in ste20D cells that harbor a preactivated Ste11 mutant, Ste11-Asp3 (Lamson et al., 2006) . Cln2 still inhibited this Ste20-independent response ( Figure 1D ), which indicates that there must be a target other than Ste20. Notably, however, partial Cln2 resistance was observed. Yet because this was true for both the Ste20-independent signaling by Ste11-Asp3 (Figure 1D ) and the Ste20-dependent signaling by Ste11-Cpr ( Figure 1C ), it did not reflect the participation of Ste20 per se. Rather, we suggest that Cln2 inhibition is strongest when it can antagonize two successive signaling steps that each rely on Ste5 membrane localization and that it becomes incomplete when the first step is bypassed by prelocalization or preactivation of Ste11. Further experiments showed that Cln2/CDK inhibition of pheromone response could be reversed by strengthening the Ste5-membrane interaction. First, mutations in the PM domain (Winters et al., 2005) that enhance membrane binding (T52L, Q59L, or a T52L Q59L double mutant) reduced Cln2 inhibition ( Figure 1F , left) from 89% (wildtype [WT] ) to 34% (T52L Q59L). Second, by replacing the native Ste5 PM domain with foreign membranebinding motifs (Winters et al., 2005) , we found that signaling remained Cln2 sensitive when we used a relatively weak motif, the PH domain from PLCd, but that signaling became Cln2 resistant when we used two tandem copies of this same motif ( Figure 1F, right) . The PM domain can also target Ste5 into the nucleus (Winters et al., 2005) , but Cln2 sensitivity was not changed by a PM domain mutation (NLSm; Figure 1E ) that specifically disrupts nuclear localization (Winters et al., 2005) . Collectively, our results suggest that Cln/CDK antagonizes the ability of the Ste5 PM domain to mediate membrane-localized signaling.
Multiple CDK Sites Flanking the Ste5 PM Domain Regulate Signaling Of 15 possible CDK sites (i.e., SP or TP) within Ste5, eight are concentrated around the PM domain ( Figure 2A ). This conspicuous clustering, when coupled with results described above, suggested that phosphorylation at one or more of these sites might regulate Ste5 signaling. Indeed, small deletions on either side of the Ste5 PM domain conferred partial Cln2 resistance ( Figure S1B ). Therefore, we replaced the Ser or Thr residues at all eight SP/TP sites with nonphosphorylatable Ala residues. This ''Ste5-8A'' mutant remained fully capable of pheromone response but was now completely resistant to Cln2 inhibition (Figures 2B and S1C) . This phenotype was specific to the Ste5-8A mutant, as a previously described Ste20 mutant, Ste20-13A, which lacks 13 CDK sites (Oda et al., 1999) , conferred no Cln2 resistance in parallel tests ( Figure 2B ). Furthermore, the Cln2 resistance displayed by Ste5-8A was separable from any possible effects on Ste5-Gbg binding because Gbg-independent signaling by P GAL1 -STE5-Q59L became resistant to Cln2 when Ste5 harbored the 8A mutations ( Figure 2C ). We also examined Ste5-8A signaling in synchronous cultures ( Figure 2D ). As cells progressed through the cell cycle, pheromone response was monitored by transcriptional induction of a FUS1-lacZ reporter and by phosphorylation of the MAPK Fus3. By either assay, Ste5-8A largely disrupted the normal cellcycle periodicity of pheromone response. Some fluctuation remained (especially at times immediately after release from cdc15 arrest), which could represent a minor effect of cell-cycle position on other targets or a nonspecific effect of the temperature-shift protocol. Overall, however, it is clear that the Ste5-8A mutant confers a very strong, if not complete, resistance to G1 CDK regulation of pheromone response.
To discover which of these eight Ste5 sites governs CDK regulation, we replaced individual Ser or Thr sites with Ala residues. Remarkably, none of the eight single (1A) mutants displayed the complete Cln2 resistance that was shown by Ste5-8A, and instead most conferred weak partial resistance ( Figure 2E ) with some variation in strength. By making combined mutants, we observed gradually increasing resistance to Cln2 as more sites were removed ( Figure 2E ), yet complete resistance was seen only when all eight sites were eliminated. Conversely, however, while Cln2 could inhibit signaling to a measurable degree when Ste5 retained four or five CDK sites, inhibition was much stronger when Ste5 retained six, seven, or eight CDK sites. Clearly, then, no single site controls sensitivity to Cln2. Rather, multiple CDK sites are required to fully inhibit Ste5 signaling.
Inhibition Is Proportional to Added Negative Charge
We hypothesized that the addition of anionic phosphates next to the basic-rich PM domain would interfere with its electrostatic attraction to acidic phospholipid membranes. Although our findings had hinted that full interference might require phosphorylation at multiple Ste5 sites, it was equally possible that multiple sites merely serve to increase the likelihood of phosphorylation at one or a few sites. To address these issues, we replaced the same Ser/Thr residues with negatively charged Glu residues ( Figure 3A ). Placement of Glu residues at all eight sites (Ste5-8E) did reduce pheromone response but not as strongly as it was reduced when Ste5-WT was inhibited by Cln2 ( Figure 3B ). To explain this partial effect, we reasoned that if electrostatic interference was the operative mechanism, then the net charge might dictate the level of inhibition. Because Ser/Thr phosphorylation introduces a charge of À2, phosphorylation at eight sites would add a net charge of À16, whereas eight Glu residues would add a net charge of only À8 and thus would be less inhibitory. To test this notion, we sought to better mimic the À2 charge of each phosphate by using two Glu residues, and so we replaced the SP or TP dipeptides at each of the eight Ste5 sites with EE dipeptides ( Figure 3A ). Indeed, pheromone response by this ''Ste5-16E'' mutant was reduced to a level similar to that seen when Ste5-WT was inhibited by Cln2 ( Figure 3B ). This strong effect required EE dipeptides at all eight sites because EE dipeptides at only four sites either before or after the PM domain (Ste5-up8E or Ste5-dn8E) caused only a partial reduction, which was reminiscent of when the eight Glu residues were distributed among all eight sites (Ste5-8E) except that signaling could be further inhibited by Cln2 via the remaining four CDK sites. Several observations suggest that the strong (B) Elimination of eight N-terminal CDK sites in Ste5 (Ste5-8A) causes resistance to Cln2. Response to a factor was measured in ste5D ± P GAL1 -CLN2 cells expressing Ste5 variants (WT or 8A) from the native STE5 promoter or in ste20D ± P GAL1 -CLN2 cells expressing Ste20 variants (WT or 13A) from the native STE20 promoter. Bars show mean ± SD (n = 8).
(C) CDK resistance caused by 8A mutations restores membrane signaling independent of Ste5-Gbg interaction. Gbg-independent signaling was activated by P GAL1 -STE5-Q59L ± 8A in ste4D ste5D cells ± P GAL1 -CLN2. Bars show mean ± SD (n = 7). (D) The Ste5-8A mutant disrupts cell-cycle periodicity of pheromone response. Cells (cdc15-2 or cdc15-2 STE5-8A) were synchronized in late M phase by arrest at 36 C and then transferred to 25 C. At various times, response to brief treatment with a factor was monitored (see Experimental
Procedures). Top panel shows FUS1-lacZ induction (mean of four trials). Bottom panel shows Fus3 activation (phospho-Fus3), which was measured using phospho-specific antibodies (mean of six trials). Arrows mark the times of bud emergence (see Figures S1D and 5G) . (E) Ste5 phosphorylation sites were replaced with Ala residues either singly (1A) or in various combinations (2A, 3A, 4A, or 8A). Response to a factor was tested in ste5D strains ± P GAL1 -CLN2 (mean + SD, n = 8-16).
signaling deficit of the Ste5-16E mutant reflects a specific effect on the Ste5 PM domain and not a complete inactivation of Ste5. First, the Ste5-16E mutant showed normal protein levels ( Figure 3C ), and it still bound Ste4 (Gb; Figure 3D ). Second, the Ste5-16E mutant could still mediate basal signaling from an activated Ste11 derivative, Ste11-4 ( Figure 3E ), which does not require the Ste5 PM domain (Mahanty et al., 1999; Winters et al., 2005) . Third, as with inhibition by Cln2 (see Figure 1C) , the 16E mutation inhibited Ste5-Q59L but not Ste5-CTM ( Figure 3F ) and therefore only blocks membrane signaling that requires the Ste5 PM domain. A control mutant with AA dipeptides at all eight sites was not informative because it was poorly expressed and completely defective in all assays. We traced this to the fact that an AA dipeptide was not tolerated at site three or four (data not shown). By allowing sites three and four to harbor only single replacements (either A or E) and by replacing the six other sites with AA or EE dipeptides, which generated ''Ste5-14A'' and ''Ste5-14E,'' we found that Ste5-14A remained functional (and fully resistant to Cln2), whereas Ste5-14E was strongly inhibited ( Figure 3B ). Therefore, the EE phenotypes reflect the addition of charge rather than the multiplicity of mutations. As with inhibition by Cln2, the Glu replacements affected membrane-based signaling in general rather than Gbgtriggered signaling in particular because they also disrupted Gbg-independent signaling by Ste11-Cpr ( Figure 3G ). Again, the degree of inhibition was proportional to the added negative charge. Notably, Ste5-14E retained more function than Ste5-16E did, which suggests that 16 negative charges are more inhibitory than 14 negative charges are. This agrees with our finding that removing (A) Glu-replacement mutations at CDK sites. S/T residues were replaced with E or A, and SP/TP dipeptides were replaced with EE or AA as indicated.
(B) Inhibition of Ste5 signaling is proportional to added negative charge. Ste5 mutants were tested for a factor response in ste5D cells ± P GAL1 -CLN2. Ste5 ''up4A'' and ''dn4A'' refer to Ala mutations at sites 1-4 and 5-8, respectively. Bars indicate FUS1-lacZ levels relative to Ste5-WT (mean ± SD, n = 6).
(C) An anti-myc blot showing levels of Ste5-myc 13 mutants expressed in ste5D cells is shown.
(D) The Ste5-16E mutant can still bind Ste4. Extracts of ste4D ste5D cells coexpressing Ste5-myc and GFP-Ste4 (after 3 hr induction of P GAL1 -GFP-STE4) were analyzed by immunoprecipitation (IP) and immunoblotting (blot) as indicated. Ste5-C180A served as a control that is defective at binding Ste4 (Feng et al., 1998) . (E) Ste5 Glu mutants are competent to mediate basal signaling (i.e., no a factor) activated by Ste11-4 in ste4D ste5D ste20D cells. Bars indicate mean ± SD (n = 4). (F) The 16E mutations only inhibit signaling that requires the Ste5 PM domain. FUS1-lacZ (mean ± SD, n = 3-6) was induced in ste4D ste5D cells (without a factor) by P GAL1 -driven expression of Ste5, Ste5-Q59L, or Ste5-CTM, each of which either did contain the 16E mutations (+16E) or did not contain the 16E mutations (À16E). Anti-GFP blots confirmed that protein levels were unaffected by the 16E mutations (data not shown).
(G) Glu mutants disrupt Gbg-independent, membrane-localized signaling. Signaling (mean ± SD, n = 6) was activated in ste4D ste5D cells (without a factor) by coexpression of P GAL1 -STE11-Cpr with the indicated Ste5 derivatives.
(H) Ste5 derivatives containing various Ala or Glu mutations were coexpressed in ste4D ste5D cells with either Ste4-WT or Ste4 mutants (K55E or N157H S175P) that weaken Ste5 binding Winters et al., 2005) . Response to a factor was measured (mean ± SD, n=6).
single CDK sites confers partial Cln2 resistance. Because the Ste5 PM domain normally acts cooperatively with Ste5-Gbg binding (Winters et al., 2005) , we predicted that the inhibitory effect of a small number of negative charges would be enhanced when Ste5-Gbg affinity is reduced. Indeed, when using Ste4 (Gb) mutants with reduced binding to Ste5, we could now detect inhibition by one to four added Glu residues ( Figure 3H ). Thus, a small number of charges have measurable inhibitory potential, but multiple charges are necessary when the interactions governing Ste5 membrane recruitment occur with normal affinity. Collectively, the Glu-replacement phenotypes show that added negative charges disrupt membrane signaling that is mediated by the Ste5 PM domain and that the requirement for multiple CDK sites truly reflects a need for adding multiple phosphates.
G1 CDK Activity Disrupts Ste5 Membrane Localization
Using a Ste5-GFP 33 fusion expressed at native levels (Winters et al., 2005) , we found that P GAL1 -CLN2 inhibited pheromone-induced membrane recruitment of Ste5-WT but not Ste5-8A ( Figure S2A ). We also used the hyperactive Ste5 variant Ste5-Q59L (Winters et al., 2005) in order to examine membrane localization that is mediated specifically by the Ste5 PM domain but which is independent of upstream factors (e.g., pheromone and Gbg) or downstream signaling consequences (e.g., transcriptional induction and cell-cycle arrest). Expression of Cln2 displaced Ste5-Q59L from the plasma membrane ( Figure 4A ), and this effect was blocked by the 8A mutations (Ste5-Q59L+8A). Results were similar in strains lacking Ste20 or lacking the MAPKs Fus3 and Kss1 ( Figure S2 ), which rules out any contribution from Cln2/CDK phosphorylation of Ste20 Wu et al., 1998) or MAPK phosphorylation of Ste5 (Kranz et al., 1994; Flotho et al., 2004; Bhattacharyya et al., 2006) . Because these experiments were performed in nonsignaling strains, the effect of Cln2 was not due to a shift from G1-arrested cells to cycling cells. Thus, Cln2/CDK actively inhibits Ste5 membrane localization mediated by the PM domain. To address whether these localization effects were due to added negative charge, we examined the Glu-replacement mutations. In agreement with its signaling phenotypes (see Figure 3F ), the 16E mutation disrupted Ste5-Q59L membrane localization, which depends on the PM domain, but did not disrupt membrane localization of Ste5-CTM, which is independent of the PM domain ( Figure 4B ). Furthermore, displacement of Ste5 can be ascribed to a local effect on the PM domain (rather than more global changes in Ste5) because Glu mutations blocked membrane localization of N-terminal Ste5 fragments (Figure 4C ). When membrane binding by an N-terminal fragment was enhanced using the Q59L mutation ( Figure 4C , bottom), displacing it required greater negative charge (i.e., 16E rather than 8E), which suggests that competition between attractive and repulsive interactions determines the net membrane affinity. Collectively, these results indicate that phosphorylation near the Ste5 PM domain disrupts plasma membrane binding.
Cln2-Dependent Phosphorylation of Ste5
To test if Cln2/CDK directly phosphorylates Ste5, we performed in vitro kinase assays. As a substrate we (A) Localization of GFP-Ste5-Q59L ± 8A, expressed from the GAL1 promoter in ste4D ste7D cells ± P GAL1 -CLN2. Note that hyperpolarized bud growth is due to Cln2 overexpression and not to mating signaling. Also see Figure S2B .
(B) The 16E mutations disrupt Ste5 membrane localization that is mediated by the PM domain (Q59L) but not Ste5 membrane localization that is mediated by a foreign transmembrane domain (CTM). At top, membrane localization induces mating-pathway signaling, which causes pear-shaped ''shmoo'' morphology. At bottom, localization results were similar in a nonsignaling strain (ste4D ste7D).
(C) Negative charge disrupts membrane localization of Ste5 N-terminal fragments. Localization was compared (in ste4D ste7D cells) for WT and mutant derivatives of GFP-Ste5(1-214) and GST-GFP-Ste5(1-125), which can localize to the membrane in the absence of pheromone, Gbg, and other Ste5 sequences (Winters et al., 2005) .
used a purified Ste5 fragment (residues 1-125) that encompasses the PM domain and all eight N-terminal CDK sites. Purified Cln2/Cdc28 phosphorylated the WT Ste5 fragment, and this was severely reduced by the 8A or 8E mutations ( Figure 5A ). Thus, the N terminus of Ste5 can serve as a direct Cln2/CDK substrate, and the CDK sites are required for phosphorylation. In vivo, Cln2 overexpression promoted Ste5 phosphorylation as evidenced by reduced electrophoretic mobility ( Figure 5B ) that was reversed by subsequent phosphatase treatment ( Figure 5C ). This agrees with a previous report that the phosphorylation status of Ste5 in vivo depends on Cdc28 (Flotho et al., 2004) . The Ste5 mobility shift was consistent with multiply phosphorylated forms, as it was comparable to the Ste5-16E mutant, which mimics phosphorylation at all eight N-terminal sites ( Figure 5B ). Furthermore, the effect of Cln2 on Ste5 mobility required the N-terminal CDK sites because Ste5-8A and Ste5-16E were unaltered by Cln2 ( Figure 5B ). Results were similar in strains lacking Fus3 and Kss1 ( Figure 5B , bottom), which rules out any contribution from Ste5-affiliated MAPKs (which can also phosphorylate SP/TP motifs). Unlike Cln2, overexpression of other cyclins (i.e., Cln3, Clb5, or Clb2) did not alter Ste5 mobility ( Figure 5D ), which agrees with their inability to inhibit pheromone signaling (Oehlen and Cross, 1994; . Thus, Ste5 is a specific substrate of Cln2/CDK activity in vivo, and the relevant phosphorylation sites correspond to those that allow Cln2 to regulate Ste5 signaling. Next, we wished to follow cell-cycle-dependent changes in (C) The Ste5 mobility shift is due to phosphorylation. Ste5-HA 3 was immunoprecipitated from ste5D ± P GAL1 -CLN2 strains and treated with calf intestinal phosphatase (CIP). (D) Effects on Ste5 mobility are specific to Cln2. Ste5-HA 3 derivatives (WT, 8A, DNLS, and DNLS+8A) were analyzed as in (B) using various P GAL1 -cyclin strains. (E) Ste5 DNLS is more fully modified by Cln2. Ste5-HA 3 derivatives were analyzed as in (B).
(F) Ste5 DNLS modification is elevated after Start and requires Cln1 and Cln2. WT and mutant strains (''cln1,2'' = cln1 cln2) expressing Ste5-HA 3 (DNLS or DNLS+8A) were incubated for 3 hr at 37 C.
(G) Modification of the Ste5 N terminus is cell-cycle dependent. Cells (cdc15-2 or cdc28-13) harboring Ste5-HA 3 (DNLS or DNLS+8A) were arrested at 37 C for 3 hr then transferred to 25 C to resume cycling. Samples were collected at 20 min intervals (0-180 min). As cdc15 cells arrest with large buds, emergence of small buds was used to follow cell-cycle progression (cf. Figure S1D) . In (B)-(G), Ste5-HA 3 derivatives were expressed from the native STE5 promoter.
Ste5 phosphorylation, but our efforts were hindered by the low fraction of Ste5 that showed a clear mobility shift. While a technical issue could be partly to blame (e.g., phosphatase activity in cell lysates), we wondered if Ste5 molecules in different subcellular locales might be modified to different extents. Indeed, when Ste5 was restricted to the cytoplasm by using the ''DNLS'' allele (Winters et al., 2005) , Cln2 expression could modify nearly all Ste5 molecules ( Figures 5D and 5E ). Phosphorylation of Ste5 DNLS resembled that of WT Ste5 in other respects, including a specific requirement for Cln2 and for the eight N-terminal CDK sites ( Figures 5D and 5E ). By exploiting these favorable detection properties, we saw that Ste5
DNLS phosphorylation was elevated in cells arrested immediately after Start (cdc4, cdc53, or cdc34) but not when Cln1 and Cln2 were absent (cdc34 cln1 cln2) nor in cells arrested in G1 (cdc28-4 or cdc28-13; Figure 5F ). Furthermore, in synchronous cultures, phosphorylation of Ste5
DNLS fluctuated during the cell cycle, peaking at the onset of budding ( Figure 5G ). Thus, modification of the N-terminal CDK sites in Ste5 occurs as cells pass Start.
CDK-Resistant Signaling Causes Aberrant Cell-Cycle Arrest
To understand why it is beneficial to inhibit pheromone signaling as cells pass Start, we explored the physiological consequences of CDK-resistant Ste5 mutants. First, we examined the G1 specificity of pheromone arrest. Unlike WT cells, which arrested uniformly in G1, a significant fraction of STE5-8A cells ($15%) arrested at a post-Start stage with 2N DNA content ( Figure 6A ). The Ste5-8A phenotype was dominant to the WT, and an increasing fraction of 2N arrest was observed as more CDK sites were removed from Ste5 ( Figure 6B ), which suggests that it reflects ectopic (i.e. not G1) signaling by CDK-resistant Ste5 (rather than a leaky G1 arrest). Indeed, the post-Start arrest phenotype required the STE5-8A cells to be cycling at the time of pheromone addition and was not observed when pheromone was added to a uniform population of G1 cells ( Figures 6C  and S3) . Also, pheromone treatment of cycling STE5-8A cells induced a unique morphology in which mating projections appeared to emanate from cell buds ( Figures  6C and S4) , which suggests that signaling responses occurred during the budding phase of the cell cycle. Remarkably, elimination of only one or two CDK sites in Ste5 caused a measurable increase in 2N arrest (Figure 6B) , which shows that full inhibition of Ste5 via multiple CDK sites serves a physiologically important function. Accordingly, a substantial level of 2N arrest was also seen when cells expressed Ste5-8E, which mimics a form with four added phosphates but which cannot be inhibited further by Cln2/CDK. We conclude that a failure of G1 CDKs to downregulate the mating MAPK pathway is detrimental, as it allows pheromone to arrest cells at an inappropriate cell-cycle stage. Because STE5-8A cells can arrest at either G1 or post-Start stages, the percentage that arrest at the latter stage (usually $15% 2N) likely reflects the fraction of cells in the asynchronous culture that were between the two arrest points. Indeed, when pheromone was added to STE5-8A cultures at different times after leaving G1, the level of 2N arrest roughly correlated with the fraction of the initial cell population that was in S phase ( Figure S3) . Hence, cells outside this susceptible window likely arrest in G1. Consistent with this view, the majority of STE5-8A cells could be trapped at the 2N stage when G1 arrest mechanisms were bypassed. Specifically, overexpression of the B-type cyclin Clb5 can push cells through Start even in the presence of pheromone, thereby making WT cells pheromone resistant , and references therein). In STE5-8A cells, however, Clb5 overexpression could still push cells through Start, but the cells arrested in response to pheromone and did so almost entirely at the 2N stage ( Figure 6D ). Therefore, signaling by CDK-resistant Ste5 has a dangerous potential to disrupt events during a post-Start window of the cell cycle.
CDK-Resistant Ste5 Permits Far1-Independent Arrest
To further explore the consequences of CDK-resistant signaling, we tested the role of Far1, which is ordinarily required for pheromone-induced arrest (Chang and Herskowitz, 1990) . Strikingly, the CDK-resistant Ste5-8A mutant restored pheromone arrest to far1D cells ( Figure 6E ). Removal of as few as one or two CDK sites in Ste5 allowed significant suppression of the far1D arrest defect, and removing more sites caused even stronger suppression ( Figures 6F and S5A) . Thus, Far1 becomes dispensable when Ste5 signaling cannot be inhibited. Indeed, far1D cells could be arrested ( Figure 6G ) by activating the mating pathway with CDK-resistant constructs (P GAL1 -STE5-Q59L+8A, P GAL1 -STE5-CTM) but not with CDK-sensitive constructs (P GAL1 -STE4, P GAL1 -STE5-Q59L). Far1-independent arrest has been observed in previous studies but remains poorly understood (Chang and Herskowitz, 1990; Valdivieso et al., 1993; Tyers, 1996; Cherkasova et al., 1999) . Our results indicate that pheromone signaling is capable of robust growth arrest without Far1, but this is masked in far1D cells because the absence of Far1 allows Cln/CDK to downregulate Ste5.
Pheromone signaling in far1D STE5-8A cells caused arrest at more than one stage because treated cultures showed a heterogeneous mix of 1N and 2N cells ( Figures  6H and S5B ) as well as unbudded and budded cells (data not shown) despite an immediate cessation of proliferation ( Figure S5C ). The G1 arrest appeared somewhat leaky and could be counteracted by G1 CDK activity (Figure S5B ). Most notably, Far1 proved entirely dispensable for the post-Start arrest because the near-uniform 2N arrest seen in STE5-8A cells overexpressing Clb5 ( Figure 6D ) was independent of Far1 ( Figure 6H) . Altogether, our results indicate that CDK-resistant signaling by Ste5-8A can impede cell-cycle progression of both G1 and postStart cells in a Far1-independent manner. Therefore, cell-cycle control of Far1 (McKinney et al., 1993; Henchoz et al., 1997) is not sufficient for cells to escape the arrest effects of pheromone, and instead downregulation of Ste5 is also critical.
DISCUSSION
Mechanism for Cell-Cycle Regulation of MAP Kinase Cascade Signaling
In this study we define a mechanism by which G1 CDKs inhibit signaling through the yeast mating MAPK cascade. We show that the MAPK cascade scaffold protein Ste5 is the target of this inhibition and that G1 CDK activity inhibits signaling by phosphorylating sites that flank a membranebinding domain in Ste5. Our findings support a model in which these negatively charged phosphates disrupt Ste5 membrane association by electrostatic interference (Figure 7A) . Hence, through the use of two weak interactions that cooperatively control its membrane recruitment, Ste5 serves as an integration point for both external and internal regulatory cues ( Figure 7B ) in a way such that signaling is activated only when two conditions are satisfied (i.e., when pheromone is present and the cell-cycle stage is appropriate). The physiological benefit of this arrangement is that it restricts pheromone arrest to G1, thus preventing inappropriate disruption of cell-cycle progression in cells that have passed Start. The regulatory CDK sites in Ste5 lie in sequences flanking the PM domain that are dispensable for its normal signaling role (Winters et al., 2005 ; see also Figure S1B ) and that are predicted to be mostly random coil ( Figure S6 ). Hence, rather than affecting a specific tertiary structure, the phosphorylated N terminus of Ste5 may behave as an unstructured electronegative mass, thereby making juxtaposition to its target energetically unfavorable. This mode of regulation may be generally applicable where phosphorylation serves to disrupt interactions. Phosphorylation of Ste5 provides a variation on ''electrostatic switch'' mechanisms seen in other signaling proteins such as Src or MARCKS, in which membrane interactions are disrupted by phosphorylation within a membranebinding domain (McLaughlin and Aderem, 1995) . In Ste5, the use of sites distal to the membrane-binding domain may impose a requirement for adding multiple phosphates, which is likely to be advantageous to the regulatory circuit (see below).
Multisite Phosphorylation as a Sensor for High CDK Activity
Inhibition of Ste5 signaling requires phosphorylation at multiple CDK sites, and maximal inhibition of Ste5 is required to avoid aberrant arrest. This behavior suggests that multisite phosphorylation of Ste5 serves as a sensor for high G1 CDK activity, so that signaling is not fully inhibited until CDK activity is high enough to promote cellcycle entry. Conceptually, this tactic is similar to that used by the B-type cyclin/CDK-inhibitor protein Sic1, which must be phosphorylated on at least six CDK sites to trigger its degradation and the resultant progression into S and M phases (Nash et al., 2001) . In each example, multisite phosphorylation likely enables a sharp phenotypic switch between distinct cell-cycle stages. Unlike Sic1, we saw no indication that CDK phosphorylation (or added Glu residues) affects Ste5 protein stability. Moreover, the effects of CDK on Ste5 may be rapidly reversible because chemical inactivation of Cdc28 can immediately restore pheromone response to post-Start cells (ColmanLerner et al., 2005) . Thus, robust dephosphorylation by cellular phosphatases may also help enforce a demand for high G1 CDK levels to inactivate Ste5 signaling.
Cell-Cycle Arrest by Pheromone
Cell-cycle control of Ste5 signaling is necessary to avoid an aberrant pheromone arrest. The best-known mediator of pheromone arrest is the CDK-inhibitor Far1, yet for years it has been evident that Far1-independent arrest pathways must exist because Far1 is dispensible in cells that lack Cln2 (Chang and Herskowitz, 1990) or all three G1 cyclins (Tyers, 1996; . Our results show that MAPK signaling can arrest growth without Far1, but this is ordinarily masked in far1D cells because Ste5 gets inactivated by G1 CDKs ( Figure 7C ). Hence, when Ste5 cannot be inhibited, the Far1-independent arrest is revealed. This can explain the preferential ability of cln2D to suppress far1D (Chang and Herskowitz, 1990) because, of the three G1 cyclins, Cln2 is the strongest at inhibiting pheromone response (Oehlen and Cross, 1994) . Therefore, although cells eliminate Far1 as they pass Start (McKinney et al., 1993; Henchoz et al., 1997) , this regulation is essentially futile without also downregulating Ste5 signaling.
The mechanisms by which CDK-resistant Ste5 signaling can impede cell-cycle progression are largely unknown. The ability of Ste5-8A to trigger a G1 arrest (or delay) without Far1 is consistent with reports that pheromone can repress G1/S transcription (Valdivieso et al., 1993; Cherkasova et al., 1999) . This repression may normally act in conjunction with Far1 to promote a robust, stable G1 arrest, yet it may still allow a weak G1 arrest in far1D cells. The post-Start arrest is more enigmatic. A similar phenotype was seen in cells lacking G1 cyclins or expressing a stable form of Far1 (McKinney and Cross, 1995) . In light of our findings, these prior cases may result from disrupted Cln/CDK regulation of Ste5. The window of susceptibility to post-Start arrest roughly overlaps S phase, which is consistent with the period in which pheromone signaling is normally downregulated (Oehlen and Cross, 1994) , and preliminary work suggests that the 2N cells cannot enter mitosis (S.C.S. and P.M.P., unpublished data), but the molecular cause remains unknown. Possibly, signaling events that ordinarily help promote G1 arrest (e.g., CDK inhibition and transcriptional repression) can also block later cell-cycle steps if signaling is unabated. Or, MAPK signaling during S phase might induce DNA damage or replication errors, thus triggering a checkpoint arrest. Alternatively, physiological changes induced by the mating pathway (e.g., cytoskeletal rearrangements) may clash with cell division due to biochemical incompatibility or competition. In any scenario, downregulation of Ste5 would allow cells to properly commit to a new division cycle by eliminating impediments to cell-cycle progression.
Coordinating Signaling with Cell-Cycle Stage
The discovery that cells sharply alter their sensitivity to extrinsic stimuli upon commitment to division played an important role in the formulation of early models for the cell cycle (Hartwell et al., 1974) . Sharp transitions between distinct cell-cycle stages can be ensured by feedback loops (Brandman et al., 2005) . In the pheromone response pathway, mutual reinforcement between Ste5 and Far1 (in which Ste5-dependent signaling activates Far1 and Far1 blocks inactivation of Ste5) establishes a positive feedback loop. Conversely, Cln/CDK inhibition of both proteins can facilitate a decisive switch between conflicting states (i.e., arrest versus proliferation).
During animal development, control of cell fate by external signals often occurs in the context of carefully orchestrated patterns of cell division (Vidwans and Su, 2001 ). Thus, it may be generally important to coordinate the response to differentiation signals with cell-division status. While it is common for MAPK cascades to regulate the cell cycle, the reciprocal regulation is less well appreciated, yet its utility is clearly demonstrated by the behavior of the pheromone response pathway. Such mutual antagonism can also occur in pathways that do not involve MAPKs, as in the TGFb pathway, where antiproliferative signaling by Smad3 is inhibited by G1 CDKs (Matsuura et al., 2004) . Thus, while the mechanisms may vary, we expect that the beneficial role of coordinating signaling with cell-cycle stage will be shared by other antiproliferative pathways.
EXPERIMENTAL PROCEDURES
Strains and Plasmids
Yeast strains are listed in Table S1 . Information on strain construction can be found in the Supplemental Experimental Procedures. Plasmids are listed in Table S2 .
Signaling Assays FUS1-lacZ induction and b-galactosidase assays were performed as described (Pryciak and Huntress, 1998; Lamson et al., 2002) . Activation of FUS1-lacZ by galactose-inducible constructs in the presence and absence of P GAL1 -CLN2 was measured 3 hr after addition of 2% galactose to cultures grown in 2% raffinose media. To measure effects of P GAL1 -CLN2 on FUS1-lacZ induction by pheromone, cells were grown in 2% raffinose media then induced with 2% galactose for 1 hr, followed by induction with 5 mM a factor for an additional 2 hr. For FUS1-lacZ experiments not involving P GAL1 -CLN2, cells grown in glucose media were treated with 5 mM a factor for 2 hr.
For signaling in synchronous cultures, cdc15 strains AA2596 and PPY1761 harbored either pPP1044 (FUS1-lacZ) or pPP1513 (Fus3-myc 13 ). Cultures in selective media were diluted into YPD and grown overnight at 25 C, shifted to 36 C for 3 hr, then pelleted and resuspended in YPD at 25 C to release the mitotic block. To measure FUS1-lacZ induction, aliquots were harvested every 15 min and treated with 10 mM a factor for 22 min. Induction was stopped by transfer to an ice-water bath. To measure Fus3 activation, every 30 min aliquots were treated with 5 mM a factor for 8 min. Cells were then pelleted, frozen in dry ice, and stored at À80 C. Fus3-myc 13 was immunoprecipitated from cell extracts, and phospho-Fus3 was detected by rabbit anti-phosphop44/42 blots (#9101; Cell Signaling Technology), quantified by densitometry, normalized to Fus3-myc 13 levels measured in separate antimyc blots, and expressed relative to time 0 for each experiment. Halo assays (Lamson et al., 2002 ) used 20 ml of 1 mM ( Figures 6E and  S5A ), 200 mM ( Figure S5A ), 100 mM ( Figures 6D, 6H , S1C, and S5B), or 20 mM ( Figure S1C ) a factor. Unless indicated otherwise, growth arrest was monitored after incubation for 2 days at 30 C.
FACS Analysis
For FACS experiments, bar1D strains were treated with 1 mM a factor in order to minimize the possibility of leaky arrest. Results were similar using 0.1 mM a factor (data not shown). Cells were grown to OD 660 = 0.2-0.3 in YPD and incubated ± a factor at 30 C. For experiments involving plasmids, cells grown overnight in selective media were transferred to YPD for 1.5 hr prior to a factor addition. Cells were analyzed by FACS as described (Haase and Reed, 2002) ; instead of pepsin, cells were treated with 0.2 ml Proteinase K solution (1 mg/ml in 50 mM Tris, pH 8.0) for 1 hr at 36 C.
Immunoblotting
Immunoprecipitation and yeast extract preparation used published methods (Lamson et al., 2002) . Immunoprecipitation of Ste5-myc 13 , Fus3-myc 13 , Ste5-HA 3 , and GFP-Ste4 used mouse anti-myc (9E10; Santa Cruz Biotech), anti-HA (HA.11; Covance), and anti-GFP (clones 7.1 and 13.1; Roche) antibodies. Blots were probed with rabbit antimyc (A-14; Santa Cruz Biotech), rabbit anti-HA (Y-11; Santa Cruz Biotech), or mouse anti-GFP (B34; Covance). Analysis of phosphorylationdependent mobility of Ste5-HA 3 used a lysis buffer with high salt and phosphatase inhibitors (Harvey et al., 2005) and 10% polyacrylamide (30:1 acryl:bis) gels. Phosphatase treatment of Ste5-HA 3 was performed as described (Chang and Herskowitz, 1992) .
Kinase Assays GST-Ste5 1-125 fusions (WT, 8A, and 8E) were purified from E. coli strain BL21-Codon Plus (Stratagene) using glutathione-Sepharose beads. The Cln2/Cdc28 complex was purified from Sf9 insect cells infected with recombinant baculoviruses (Nash et al., 2001 ). Cln2/Cdc28 (100 ng) was mixed with GST-Ste5 1-125 (30 mg) or histone H1 (1 mg) in 10 ml of reaction buffer (50 mM Hepes pH 7.5, 10 mM MgCl 2 , 1 mM DTT, 10 mCi [ 32 P]-g-ATP, and 100 mM cold ATP) and incubated for 30 min at 30 C. Products were resolved by SDS-PAGE and stained with Coomassie blue. Gels were then dried and analyzed by autoradiography.
Microscopy GFP fusions to Ste5 (full-length or fragments) were visualized without fixation and after induction from the GAL1 promoter with 2% galactose for 2-4 hr (Pryciak and Huntress, 1998; Winters et al., 2005) . Results representative of multiple repeated experiments are shown.
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